Twenty‐seven patients with a KRAS or BRAF (non‐V600E) mutation in the primary tumor from whom plasma was available at several timepoints during ICI treatment, predominantly at 1, 2, 4, and 6 weeks after initiation, were selected (Table S1) to determine the optimal timepoint to measure changes in ctDNA levels associated with therapy response effects. This evidence concerns the gene KRAS and neoplasm.